Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation
The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation
Sponsor: The Third Xiangya Hospital of Central South University
Listed as NCT02502110, this PHASE4 trial focuses on Paroxysmal Atrial Fibrillation and remains ongoing. Sponsored by The Third Xiangya Hospital of Central South University, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jul 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Jul 2019 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Third Xiangya Hospital of Central South University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.